Literature DB >> 23982521

Factors associated with the length of remission of psoriasis vulgaris.

Susana Coimbra1, Hugo Oliveira, Américo Figueiredo, Petronila Rocha-Pereira, Alice Santos-Silva.   

Abstract

BACKGROUND: Cardiovascular risk factors are found with significantly high frequency in psoriatic patients. Periods of remission and reactivation of lesions are common in psoriasis.
OBJECTIVE: Considering the association of chronic inflammation with the atherogenic process, we aimed to search for a possible relationship between the lipid profile, adipokine levels and body mass index (BMI) at the end of a successful treatment for psoriasis, and the length of remission of psoriasis.
METHODS: Forty-three patients were clinically and analytically studied after a successful treatment [as shown by Psoriasis Area and Severity Index (PASI)]--nine treated with topical agents, 17 with narrow-band UV light B (NB-UVB) and 17 with psoralen plus UVA-and were followed to record the length of remission.
RESULTS: The length of psoriasis remission correlated negatively and significantly with cholesterol levels, which correlated significantly and positively with C-reactive protein (CRP). In multiple linear regression analysis, cholesterol, CRP, PASI and BMI were associated with the length of remission. Patients with cholesterol levels <200 mg/dL (n = 13) presented a significantly longer remission, lower BMI and triglycerides values, and a trend towards lower PASI and CRP values than those with high cholesterol (n = 30). Considering patients according to the treatment used, cholesterol was also associated with length of remission, especially for patients treated with NB-UVB and topical therapy.
CONCLUSION: Psoriasis patients with the highest cholesterol levels presented higher BMIs, triglycerides levels and shorter remission periods. Our data suggest that the identification of potentially treatable conditions, such as dyslipidaemia and obesity, and their adequate treatment may benefit psoriasis patients by increasing the length of remission of the disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23982521     DOI: 10.1007/s40261-013-0122-9

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  19 in total

1.  Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy.

Authors:  S Coimbra; H Oliveira; F Reis; L Belo; S Rocha; A Quintanilha; A Figueiredo; F Teixeira; E Castro; P Rocha-Pereira; A Santos-Silva
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-12       Impact factor: 6.166

2.  Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease.

Authors:  Susana Coimbra; Hugo Oliveira; Flávio Reis; Luís Belo; Susana Rocha; Alexandre Quintanilha; Américo Figueiredo; Frederico Teixeira; Elisabeth Castro; Petronila Rocha-Pereira; Alice Santos-Silva
Journal:  J Dermatol Sci       Date:  2009-07-02       Impact factor: 4.563

3.  Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease.

Authors:  P Rocha-Pereira; A Santos-Silva; I Rebelo; A Figueiredo; A Quintanilha; F Teixeira
Journal:  Clin Chim Acta       Date:  2001-01       Impact factor: 3.786

4.  Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy.

Authors:  F Bardazzi; R Balestri; E Baldi; A Antonucci; S De Tommaso; A Patrizi
Journal:  Dermatol Ther       Date:  2010 Jan-Feb       Impact factor: 2.851

5.  Principal determinants of the length of remission of psoriasis vulgaris after topical, NB-UVB, and PUVA therapy: a follow-up study.

Authors:  Susana Coimbra; Hugo Oliveira; Luís Belo; Américo Figueiredo; Petronila Rocha-Pereira; Alice Santos-Silva
Journal:  Am J Clin Dermatol       Date:  2013-02       Impact factor: 7.403

6.  C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy.

Authors:  S Coimbra; H Oliveira; F Reis; L Belo; S Rocha; A Quintanilha; A Figueiredo; F Teixeira; E Castro; P Rocha-Pereira; A Santos-Silva
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-12-11       Impact factor: 6.166

7.  The inflammatory response in mild and in severe psoriasis.

Authors:  P Rocha-Pereira; A Santos-Silva; I Rebelo; A Figueiredo; A Quintanilha; F Teixeira
Journal:  Br J Dermatol       Date:  2004-05       Impact factor: 9.302

8.  C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis.

Authors:  G Chodorowska; D Wojnowska; M Juszkiewicz-Borowiec
Journal:  J Eur Acad Dermatol Venereol       Date:  2004-03       Impact factor: 6.166

Review 9.  Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review.

Authors:  W Sterry; B E Strober; A Menter
Journal:  Br J Dermatol       Date:  2007-07-11       Impact factor: 9.302

10.  C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003.

Authors:  S Matthijs Boekholdt; C Erik Hack; Manjinder S Sandhu; Robert Luben; Sheila A Bingham; Nicholas J Wareham; Ron J G Peters; J Wouter Jukema; Nicholas E Day; John J P Kastelein; Kay-Tee Khaw
Journal:  Atherosclerosis       Date:  2005-10-28       Impact factor: 5.162

View more
  1 in total

1.  Metabolic syndrome affects narrow-band UVB phototherapy response in patients with psoriasis.

Authors:  Wang Rui; Ding Xiangyu; Xie Fang; Gong Long; Yang Yi; Wang Wenjuan; Hao Tian; Zhang Xiaoning; Zhou Yong; Fan Jianfeng; Li Hengjin; Li Chengxin
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.